Dr. Lawrence Hamann

Larry Hamann is currently Co-Founder, President and CEO of Interdict Bio, a new venture-backed stealth mode biotech. Previously, Larry was Global Head, Drug Discovery Sciences at Takeda Pharmaceuticals, and prior to that, Corporate Vice President and Global Head, Small Molecule Drug Discovery at Celgene, where his teams built a state-of-the-art platform for protein degradation therapeutics, with several molecules in clinical development.  In >30 years of drug discovery, he has led teams responsible for >18 clinical stage compounds, including the FDA approved molecules saxagliptin (Onglyza®) and daclatasvir (Daklinza®). Prior to Celgene, Larry held positions of increasing responsibility at Novartis, Bristol-Myers Squibb, and Ligand Pharmaceuticals. Larry is co-inventor on >70 patents, co-author on >90 scientific publications.  Larry was awarded the ACS Division of Medicinal Chemistry Award in 2022, and earned a PhD in Organic Chemistry from the University of Michigan.